Matthew Hall Quoted on Generic Pharmaceutical “Pay-for-Delay” Competition Penalty

February 16, 2016

A Feb. 12 Global Competition Review article titled “CMA imposes record high fine in first pay-for-delay case” discusses the £45 million fine levied by the UK’s Competition and Markets Authority against pharmaceutical companies accused of agreeing to delay selling generic versions of one company’s anti-depressant drug. In quoted and paraphrased material, McGuireWoods Brussels partner Matthew Hall notes the importance of factors that may have weighed into the decision, such as potential profits of the generic manufacturers, the scope of the patent at the heart of the agreements, and what would happen after the agreed delay. Full text of the article is available to subscribers online.